Scholarlink

Objectives <p>Contrast-enhanced CT (CE-CT) and MRI (CE-MRI) are routine examinations for staging of pancreatic cancer (PC). This study aimed to directly compare the diagnostic performance of the novel [<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT against these established modalities for initial clinical staging.</p> Methods <p>A total of 127 patients with initial PC who had simultaneously undergone [<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT, CE-CT and CE-MRI were enrolled in this retrospective study. Their clinical features and imaging data were evaluated and staged according to TNM classification. Histopathological findings or follow-up data or multidisciplinary team (MDT) discussion served as the reference standard for the final diagnosis.</p> Results <p>For primary tumor (T) staging, CE-CT and CE-MRI demonstrated equivalent performance and outperformed [<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT across all T stages except T1c. However, the PET/CT modality achieved significantly higher sensitivity, accuracy, and negative predictive value for both nodal (N) and distant metastasis (M) staging (all <i>p</i> &lt; 0.05). It changed the N stage in 26 patients, altering management in 5 (3.93%), and revised the M stage in 16 and 18 patients compared to CE-CT and CE-MRI, respectively, leading to major treatment changes in 15 (11.81%) and 17 (13.38%) patients. A SUVmax cutoff of 4.85 for lymph node metastasis provided moderate sensitivity (67.1%) and high specificity (93.7%).</p> Conclusion <p>[<sup>18</sup>F]AlF-NOTA-FAPI−04 PET/CT outperforms CE-CT and CE-MRI in evaluating N and M staging except T staging in initial pancreatic cancer, leading to a more accurate clinical staging and a more rational therapeutic decision-making. [<sup>18</sup>F]AlF-NOTA-FAPI−04 PET/CT should be considered a useful diagnostic tool for initial staging of pancreatic cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

[18F]AlF-NOTA-FAPI-04 PET/CT outperforms contrast-enhanced CT and contrast-enhanced MRI in clinical staging evaluation of patients with initial pancreatic cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Lili Lin,
  • Shuye Yang,
  • Wenxin Wang,
  • Xiang Li,
  • Yafei Zhang,
  • Guolin Wang,
  • Xue Wen,
  • Kui Zhao,
  • Jun Yang,
  • Xinhui Su

摘要

Objectives

Contrast-enhanced CT (CE-CT) and MRI (CE-MRI) are routine examinations for staging of pancreatic cancer (PC). This study aimed to directly compare the diagnostic performance of the novel [18F]AlF-NOTA-FAPI-04 PET/CT against these established modalities for initial clinical staging.

Methods

A total of 127 patients with initial PC who had simultaneously undergone [18F]AlF-NOTA-FAPI-04 PET/CT, CE-CT and CE-MRI were enrolled in this retrospective study. Their clinical features and imaging data were evaluated and staged according to TNM classification. Histopathological findings or follow-up data or multidisciplinary team (MDT) discussion served as the reference standard for the final diagnosis.

Results

For primary tumor (T) staging, CE-CT and CE-MRI demonstrated equivalent performance and outperformed [18F]AlF-NOTA-FAPI-04 PET/CT across all T stages except T1c. However, the PET/CT modality achieved significantly higher sensitivity, accuracy, and negative predictive value for both nodal (N) and distant metastasis (M) staging (all p < 0.05). It changed the N stage in 26 patients, altering management in 5 (3.93%), and revised the M stage in 16 and 18 patients compared to CE-CT and CE-MRI, respectively, leading to major treatment changes in 15 (11.81%) and 17 (13.38%) patients. A SUVmax cutoff of 4.85 for lymph node metastasis provided moderate sensitivity (67.1%) and high specificity (93.7%).

Conclusion

[18F]AlF-NOTA-FAPI−04 PET/CT outperforms CE-CT and CE-MRI in evaluating N and M staging except T staging in initial pancreatic cancer, leading to a more accurate clinical staging and a more rational therapeutic decision-making. [18F]AlF-NOTA-FAPI−04 PET/CT should be considered a useful diagnostic tool for initial staging of pancreatic cancer.